Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Correlation of rFVIII inactivation with aggregation in solution.

Wei Wang1, Drew N Kelner

  • 1Analytics & Formulation, Process Sciences, Biotechnology, Bayer Corp., 800 Dwight Way, Berkeley, California 94701, USA. wei.wang.b@bayer.com

Pharmaceutical Research
|May 13, 2003
PubMed
Summary

Recombinant FVIII (rFVIII) rapidly inactivates via aggregation in solution at 40°C. Optimal stability occurs between pH 6.6-7.0, indicating aggregation is a key factor in rFVIII instability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of different approaches for evaluation of the detection and quantitation limits of a purity method: a case study using a capillary isoelectrofocusing method for a monoclonal antibody.

Analytical biochemistry·2008
Same author

Human IgG2 antibodies display disulfide-mediated structural isoforms.

The Journal of biological chemistry·2008
Same author

Permeation of particle through a four-helix-bundle model channel.

The Journal of chemical physics·2005
Same author

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.

Vaccine·2005
Same author

Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same author

Towards automatic clustering of protein sequences.

Proceedings. IEEE Computer Society Bioinformatics Conference·2005

Area of Science:

  • Biochemistry
  • Protein Stability
  • Pharmaceutical Sciences

Background:

  • Recombinant coagulation factor VIII (rFVIII) is crucial for hemophilia A treatment.
  • Understanding rFVIII stability is essential for effective therapeutic formulation and storage.
  • Accelerated degradation studies provide insights into protein behavior under stress.

Purpose of the Study:

  • To assess the pH-dependent stability of recombinant FVIII (rFVIII) in aqueous solution.
  • To identify the mechanisms underlying rFVIII inactivation under accelerated storage conditions (40°C).
  • To correlate protein aggregation with loss of biological activity.

Main Methods:

  • Incubation of rFVIII solutions at various pH levels at 40°C.
  • Activity assessment using the one-stage clotting assay.

Related Experiment Videos

  • Analysis of aggregation and degradation via Size Exclusion High-Performance Liquid Chromatography (SEC-HPLC), SDS-PAGE, and UV spectrophotometry.

    • Main Results:

    • rFVIII exhibited rapid, pseudo first-order inactivation at 40°C across all tested pH values.
    • A U-shaped pH-stability profile was observed, with minimal inactivation rates between pH 6.6 and 7.0 (half-life ~4 days).
    • SEC-HPLC confirmed pH-dependent rFVIII aggregation, which strongly correlated with activity loss (r² = 0.97). SDS-PAGE indicated multiple aggregation pathways.

    Conclusions:

    • Full-length rFVIII is unstable in solution at elevated temperatures, undergoing rapid aggregation.
    • Both physical and chemical mechanisms contribute to rFVIII aggregation and subsequent inactivation.
    • SEC-HPLC serves as a reliable method for monitoring rFVIII stability, potentially replacing clotting assays under specific incubation conditions.